NEUROPROTECTIVE EFFECT OF METHANOLIC EXTRACT OF SARGASSUM WIGHTII ON HALOPERIDOL INDUCED CATALEPSY AND TARDIVE DYSKINESIA IN ALBINO RATS

  • S. ROUT Pharmacology, Roland Institute of Pharmaceutical Sciences, Berhampur, Odisha
  • B. RATH Pharmacology Fakir Mohan Medical College, Balasore, Odisha
  • S. K. BHATTAMISRA Pharmacology, Roland Institute of Pharmaceutical Sciences, Berhampur, Odisha
  • A. KUMAR Pharmaceutical Chemistry, Roland Institute of Pharmaceutical Sciences, Berhampur, Odisha
  • S. RATH Anatomy, MKCG Medical College, Berhampur Odisha

Abstract

Objective: The present study was designed to evaluate the neuroprotective effect of methanolic extract of Sargassum wightii on haloperidol-induced catalepsy and tardive dyskinesia in Wistar albino rats.


Methods: In this study, thirty Wistar albino rats were randomly divided into six groups. Gr-I served as control. Haloperidol (1 mg/kg intraperitoneally) was administered to rats of Gr-II to Gr-V for twenty-one consecutive days to induce catalepsy and tardive dyskinesia. Animals of Gr-II to Gr-V were orally administered with vehicle, levodopa carbidopa combination (30 mg/kg), Sargassum extract 200 and 400 mg/kg respectively. All the drugs and vehicles were given orally one hour before haloperidol injection for twenty one consecutive days. The cataleptic scores were recorded using standard bar test. Tardive dyskinesia was assessed in terms of vacuous chewing movement (VCM) and tongue protrusion (TP) scores. After behavioural testing, all animals were sacrificed on twenty-second day and various biochemical parameters like MDA, SOD and GSH were estimated in brain tissue.


Results: Chronic administration of haloperidol significantly increased cataleptic scores, VCM and TP scores. (p<0.001) Sargassum wightii extract (400 mg/kg) significantly inhibited haloperidol-induced catalepsy, VCM and TP (p<0.001) Haloperidol increased MDA and decreased SOD and GSH in brain tissue to a highly significant extent (p<0.001) Sargassum extract at 400 mg/kg also significantly reversed the haloperidol-induced alteration in brain oxidative stress markers.


Conclusion: Sargassum wightii inhibits haloperidol-induced catalepsy and tardive dyskinesia. Thus it may be used as a unique therapeutic adjunct for the prevention of neuroleptic-induced extrapyramidal symptoms, however, it has to be explored more.

Keywords: Sargassum wightii, Catalepsy, Tardive dyskinesia, Oxidative stress, Albino rat

Downloads

Download data is not yet available.

References

1. Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin 2011;29:127-48.
2. Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first-and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry 2018;17:330-40.
3. Somani RS, Kasture VS, Kasture SB. Haloperidol inhibits (-) bicucullin induced seizures and bicucullin potentiates haloperidol-induced catalepsy in mice. Indian J Pharmacol 1993;31:434-6.
4. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. PET-analysis of central D-2 and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-44.
5. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med Cambridge University Press 1980;10:55–72.
6. Kulkarni SK, Naidu PS. Isoniazid-induced orofacial dyskinesia in rats: an experimental model for tardive dyskinesia. Indian J Pharmacol 2001;33:286-8.
7. Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990;28:535-9.
8. Patil R, Hiray YA, Kasture SB. Reversal of reserpine induced orofacial dyskinesia and catalepsy by Nardostachys jatamansi. Indian J Pharmacol 2012;44:340-4.
9. Liu L, Heinrich M, Myers S, Dworjanyn S. Towards a better understanding of medicinal uses of the brown seaweed Sargassum in traditional chinese medicine: a phytochemical and pharmacological review. J Ethnopharmacol 2012;142:591-619.
10. Yende SR, Harle UN, Chaugule BB. Therapeutic potential and health benefits of Sargassum species. Pharmacogn Rev 2014;8:1-7.
11. Fazeela Mahaboob Begum SM, Hemalatha S. Characterization, in silico and in vitro determination of the antidiabetic and anti-inflammatory potential of ethanolic extract of Sargassum wightii. Asian J Pharm Clin Res 2017;10:297-301.
12. Lee SG, Kang H. Neuroprotective effect of Sargassum thunbergii (Mertens ex Roth) kuntze in activated murine microglial cells. Trop J Pharm Res 2015;14:235–40.
13. Sumithra M, Arunachalam G, Chitra V, Gowri K. Neuroprotective effect of Sargassum ilicifolium turner C. Agardh on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia in rodents. Asian J Pharm Clin Res 2016;9:93-6.
14. Wen Ning Yang, Po-Wei Chen, Chun Yung Huang. Compositional characteristics and in vitro evaluations of antioxidant and neuroprotective properties of crude extracts of fucoidan prepared from compressional puffing-pretreated Sargassum crasifolium. Marine Drugs 2017;15:183.
15. Anwar E, Erianto H, Putri HSS. Preparation of powder from brown seaweed (Sargassum plagyophyllum) by freeze-drying with maltodextrin as a stabilizer. Int J Appl Pharm 2018;10:348-53.
16. Praveen NK, Chakraborty K. Antioxidant and anti-inflammatory potential of the aqueous extract and polysaccharide fraction from brown marine macroalgae padina sp. From the gulf of mannar of peninsular India. J Coastal Life Med 2013;1:38-48.
17. Najam R, Ahmed SP, Azhar I. Pharmacological activities of Hypnea musciformis. Afr J Biomed Res 2010;13:69–74.
18. Yuvaraj Neelakandan, Venkatesan A. In vitro anti-tumor, anti-inflammatory, antioxidant and antibacterial activities of marine brown alga Sargassum wightii collected from the gulf of mannar. Global J Pharmacol 2014;8:566-77.
19. Kokate CK, Purohit AP, Gokhale SB. Pharmacognosy. Pune: Nirali Prakashan. 47th ed; 2011. p. 6.15-6.19.
20. OECD Guidelines for testing of chemicals 423; 2001.
21. Nade VS, Kawale LA, Zambre SS, Kapure AB. Neuroprotective potential of Beta vulgaris L. in Parkinson's disease. Indian J Pharmacol 2015;47:403-8.
22. Ferre S, Guix T, Prat G, Jane F, Casas M. Is experimental catalepsy properly measured? Pharm Biochem Behav 1990;35:753-7.
23. Parwez Ahmad MD, Arshad H, Kalam NA, Anshu M, Hasin MD, Shadma W. Effect of the aqueous extract of Mentha arvensis on haloperidol-induced catalepsy in albino mice. J Clin Diagnostic Res 2012;6:542-6.
24. Sivaraman D, Ratheesh KS, Palayan M. Effect of ethanolic seed extract of Mucuna pruriens on haloperidol-induced tardive dyskinesia in rats. Int J Pharm Sci Rev Res 2010;3:106-13.
25. Ohkawa H, Ohishi N, Yagi K. Assay of lipid peroxides in animal tissues by the thiobarbituric acid reaction. Anal Biochem 1979;95:351-4.
26. Sedlak J, Lindsay RH. Estimation of total protein (bound) and the nonprotein sulfhydryl groups in tissues by using Ellman’s reagent. Anal Biochem 1968;25:192-205.
27. Marklund S, Marklund G. Involvement of superoxide anion radical in the autoxidation of pyrogallol and a convenient assay of superoxide dismutase. Eur J Biochem 1974;47:469-74.
28. Elliott PJ, Close SP, Walsh DM, Hayes AG, Marriott AS. neuroleptic-induced catalepsy as a model of Parkinson’s disease. I. Effect of dopaminergic agents. J Neural Transm Park Dis Dement Sect 1990;2:79?89.
29. Aurel Popa Wagner, Smaranda Mitran, Senthilkumar Sivanesan, Edwin Chang, Ana-Maria Buga. ROS and brain diseases: the good, the bad, and the ugly. Oxidative Medicine and Cellular Longevity; 2013. p. 1-14.
30. Rajaram C, Reddy KR, Chandra Sekhar KB. Neuroprotective activity of Tephrosia purpurea against haloperidol-induced Parkinson’s disease model. Pharmacologia 2015;6:125-30.
31. Nishchal BS, Rai S, Prabhu MN, Ullal SD, Rajeswari S, Gopalakrishna HN. Effect of Tribulus terrestris on haloperidol-induced catalepsy in mice. Indian J Pharm Sci 2014;76:564-7.
32. S Pemminati, V Nair, P Dorababu, HN Gopalakrishna, MRSM Pai. Effect of ethanolic leaf extract of Ocimum sanctum on haloperidol-induced catalepsy in albino mice. Indian J Pharmacol 2007;39:87-9.
33. Dinesh Dhingra, Nidhi Gahalain. Amelioration of haloperidol-induced orofacial dyskinesia and catalepsy by Ellagic acid in rats. Int J Res Ayurveda Pharm 2016;7(Suppl 2):222-7.
34. Jitendra O Bhangale, Sanjeev R Acharya. The anti-parkinson activity of petroleum ether extract of Ficus religiosa (L.) leaves. Adv Pharmacol Sci 2016;1-9. http://dx.doi.org/10.1155/ 2016/9436106.
35. Susete Pinteus, Marco FL Lemos, Joana Silva, Celso Alves, Agnieszka Neugebauer, Rafaela Freitas, et al. An insight into Sargassum muticum cytoprotective mechanisms against oxidative stress on a human cell in vitro model. Marine Drugs 2017;15:353.
36. Bogie J, Hoeks C, Schepers M, Tiane A, Cuypers A, Leijten F, et al. Dietary Sargassum fusiforme improves memory and reduces amyloid plaque load in an Alzheimer's disease mouse model. Nature News. Nature Publishing Group; 2019.
37. Schepers M, Martens N, Tiane A, Vanbrabant K, Liu HB, Lütjohann D, et al. Edible seaweed-derived constituents: an undisclosed source of neuroprotective compounds. Neural Regen Res 2019;15:790-5.
Statistics
356 Views | 272 Downloads
Citatons
How to Cite
ROUT, S., B. RATH, S. K. BHATTAMISRA, A. KUMAR, and S. RATH. “NEUROPROTECTIVE EFFECT OF METHANOLIC EXTRACT OF SARGASSUM WIGHTII ON HALOPERIDOL INDUCED CATALEPSY AND TARDIVE DYSKINESIA IN ALBINO RATS”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 12, no. 3, Jan. 2020, pp. 1-6, doi:10.22159/ijpps.2020v12i3.36518.
Section
Original Article(s)